leadf
logo-loader
viewMGC Pharmaceuticals Ltd

MGC Pharmaceuticals ships first-ever THC formulations direct to Brazilian patients via ONIX online platform

Brazil is a strategically important market with a population of over 210 million and a pharmaceutical market value of around A$24 billion per annum, with new patients registering daily for MGC Pharma products after the first week.

MGC Pharmaceuticals Ltd - MGC Pharmaceuticals ships first THC formulations direct to patients in Brazil via ONIX online platform
MGC Pharma is the first company globally to ever supply high THC formulations directly to patients in Brazil

MGC Pharmaceuticals Ltd (ASX:MXC) has completed its first-ever shipments of the Mercury Pharma line, which includes high THC products, directly to patients in Brazil through a binding supply and distribution agreement with ONIX Empreendimentos e Participações.

The company has become the first globally to ship high THC formations directly to a patient's door in Brazil, marking a first major operational achievement.

ONIX has launched the second generation of its CANTERAMED platform to help doctors better service their patients. 

This platform has facilitated the doctor's practice with its protocols to use MGC Pharma products and register treatment results. 

CANTERAMED includes a telemedicine platform that connects patients with doctors trained to prescribe MGC Pharma products. 

“Rapidly increasing demand”

Co-founder and MD Roby Zomer said: “This is an incredible achievement as no other company has shipped high THC formulations directly to patients in Brazil before.

“We have been working closely with our Brazilian partner ONIX and remain confident that Brazil will be a huge strategically and commercially important region for us going forward.

“Feedback to date from patients in Brazil has been extremely positive and we are seeing rapidly increasing demand for our Mercury Pharma products.”

The shipment of Mercury Pharma branded products directly to patients is in compliance with Brazil’s Compassionate Use Program, following the receipt of patients’ prescriptions provided by an ONIX referring doctor.

ONIX has more than 100 referring doctors in Brazil able to prescribe cannabinoid products under the Compassionate Use Program and is targeting to have more than 300 referring doctors by the end of calendar 2020 as well as more than 1,000 by mid-2021.

The full Mercury Pharma line is now available in Brazil which, based on the company’s medical teams years of experience, includes a range of products from pure CBD (MP100) through different ratios (1:30, 1:1, 7:1, 15:1) up to pure THC products.

“Important part of our strategy”

ONIX founder Marcelo Galvão said: “We are very happy to make this announcement - it has always been an important part of our strategy to bring high THC products to Brazil.

“There are more than 30,000 patients currently using homemade oils in Brazil and those patients really need quality products that we now carry with the Mercury Pharma Line.”

ONIX is visiting doctors in the traditional pharma model educating doctors about products and is targeting to have more than 1,000 doctors with the ability to prescribe cannabinoid products to patients by mid-2021.

These initiatives are expected to continue to drive market awareness and penetration of cannabinoid products for eligible patients in Brazil.

Quick facts: MGC Pharmaceuticals Ltd

Price: 0.021 AUD

ASX:MXC
Market: ASX
Market Cap: $35.93 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MGC Pharmaceuticals Ltd named herein, including the promotion by the Company of MGC Pharmaceuticals Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

MGC Pharma 'confident' following completion of ArtemiC Phase II COVID-19 trial

MGC Pharmaceuticals Ltd's (ASX:MXC) (OTCMKTS:MGCLF) (FRA:MGC) Roby Zomer caught up with Proactive's Andrew Scott following completion of its 50-patient Phase II double-blind, placebo-controlled clinical trial for anti-inflammatory treatment, ArtemiC, on patients diagnosed with COVID-19. Final...

2 weeks, 3 days ago

3 min read